If you have been reading about Albumin conjugation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-13. Numbers and descriptions here follow the published literature rather than marketing material.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Moreover, both the refractive index and the optical absorption are found to be dispersionless over a broad wavelength range from visible to near infrared. Finally, GO film offers flexible patterning capability by using the maskless DLW method, which reduces the manufacturing complexity and requirements. As a result, a novel ultrathin planar lens on a GO thin film has been realized recently using the DLW method. The distinct advantage of the GO flat lens is that phase modulation and amplitude modulation can be achieved simultaneously, which are attributed to the giant refractive index modulation and the variable linear optical absorption of GO during its reduction process, respectively. Due to the enhanced wavefront shaping capability, the lens thickness is pushed down to subwavelength scale (~200 nm), which is thinner than all current dielectric lenses (~ μm scale). The focusing intensities and the focal length can be controlled effectively by varying the laser powers and the lens sizes, respectively. By using an oil immersion high numerical aperture (NA) objective during DLW process, 300 nm fabrication feature size on GO film has been realized, and therefore the minimum lens size has been shrunk down to 4.6 μm in diameter, which is the smallest planar micro lens and can only be realized with metasurface by FIB. Thereafter, the focal length can be reduced to as small as 0.8 μm, which would potentially increase the numerical aperture (NA) and the focusing resolution.
== Research == Aceclidine has been a subject of clinical and pharmacological research since the 1960s. Early studies in the 1970s compared its efficacy for glaucoma to that of pilocarpine, finding it produced a similar reduction in intraocular pressure with a lesser effect on accommodation. Research in the 1980s on its optical isomers determined the (+)-enantiomer was the primary source of its cholinergic activity. In the 2010s, research refocused on aceclidine as a potential treatment for presbyopia due to its pupil-selective mechanism. Under the development code PRX-100, Lenz Therapeutics conducted the Clarity 1, 2, and 3 clinical trials. Clarity 1 and 2 were Phase III trials that evaluated aceclidine 1.44 % in adults with presbyopia and met all primary and secondary endpoints for improving near visual acuity. Clarity 3 was a long-term study that confirmed the drug's safety and tolerability over a six-month period. The results of these trials formed the basis for its FDA approval in 2025.
Uranium, like all elements with an atomic number greater than 82, has no stable isotopes. All isotopes of uranium are radioactive because the strong nuclear force does not prevail over electromagnetic repulsion in nuclides containing more than 82 protons. Nevertheless, the two most stable isotopes, 238U and 235U, have half-lives long enough to occur in nature as primordial radionuclides, with measurable quantities having survived since the formation of the Earth. These two nuclides, along with thorium-232, are the only confirmed primordial nuclides heavier than nearly-stable bismuth-209. Natural uranium consists of three major isotopes: uranium-238 (99.28% natural abundance), uranium-235 (0.71%), and uranium-234 (0.0054%). There are also five other trace isotopes: uranium-240, a decay product of plutonium-244; uranium-239, which is formed when 238U undergoes spontaneous fission, releasing neutrons that are captured by another 238U atom; uranium-237, which is formed when 238U captures a neutron but emits two more, which then decays to neptunium-237; uranium-236, which occurs in trace quantities due to neutron capture on 235U and as a decay product of plutonium-244; and finally, uranium-233, which is formed in the decay chain of neptunium-237. Additionally, uranium-232 would be produced by the double beta decay of natural thorium-232, though this energetically possible process has never been observed. Uranium-238 is the most stable isotope of uranium, with a half-life of about 4.463×109 years, roughly the age of the Earth.
In 1931, when he was 16, Thomas left school to become a reporter for the South Wales Daily Post, where he remained for some 18 months. After leaving the newspaper, Thomas continued to work as a freelance journalist for several years, during which time he remained at Cwmdonkin Drive. He continued to add to his notebooks, which would eventually comprise over 200 poems in five books compiled between 1930 and 1935. Of the 90 poems he published, half were written during these years. The discovery in 2014 of the fifth notebook containing 16 poems, compiled between 1934 and August 1935, had substantial implications for the understanding of Thomas's poetic development as well as leading to a revision of the hitherto accepted chronology of composition dates for the poems.
===== OECD ===== During an address to Argentine businesspeople in October 2024, Peña stated that one of the principal goals of his government is for Paraguay to become a member of the Organisation for Economic Co-operation and Development (OECD). He explained that, to achieve this goal, it is essential to continue promoting development in key areas such as education and security.
Sources: en.wikipedia.org
=== I: Diseases of the circulatory system === (I25.4) Coronary arteriovenous fistula, acquired (I28.0) Arteriovenous fistula of pulmonary vessels Pulmonary arteriovenous fistula: between an artery and vein of the lungs, resulting in shunting of blood. This results in improperly oxygenated blood. (I67.1) Cerebral arteriovenous fistula, acquired (I77.0) Arteriovenous fistula, acquired (I77.2) Fistula of artery
is the molecular mass. In general, however, the viscosity of a system depends in detail on how the molecules constituting the system interact, and there are no simple but correct formulas for it. The simplest exact expressions are the Green–Kubo relations for the linear shear viscosity or the transient time correlation function expressions derived by Evans and Morriss in 1988. Although these expressions are each exact, calculating the viscosity of a dense fluid using these relations currently requires the use of molecular dynamics computer simulations. Somewhat more progress can be made for a dilute gas, as elementary assumptions about how gas molecules move and interact lead to a basic understanding of the molecular origins of viscosity. More sophisticated treatments can be constructed by systematically coarse-graining the equations of motion of the gas molecules. An example of such a treatment is Chapman–Enskog theory, which derives expressions for the viscosity of a dilute gas from the Boltzmann equation.
== Structural function in proteins == Since the asparagine side-chain can form hydrogen bond interactions with the peptide backbone, asparagine residues are often found near the beginning of alpha-helices as asx turns and asx motifs, and in similar turn motifs, or as amide rings, in beta sheets. Its role can be thought as "capping" the hydrogen bond interactions that would otherwise be satisfied by the polypeptide backbone. Asparagine also provides key sites for N-linked glycosylation, modification of the protein chain with the addition of carbohydrate chains. Typically, a carbohydrate tree can solely be added to an asparagine residue if the latter is flanked on the C side by X-serine or X-threonine, where X is any amino acid with the exception of proline. Asparagine can be hydroxylated in the HIF1 hypoxia-inducible transcription factor. This modification inhibits HIF1-mediated gene activation.
The weight of the displaced fluid is directly proportional to the volume of the displaced fluid (if the surrounding fluid is of uniform density). The apparent weight of the object in the fluid is reduced, because of the force acting on it, which is called upthrust. In simple terms, the principle states that the buoyant force (Fb) on an object is equal to the weight of the fluid displaced by the object, or the density (ρ) of the fluid multiplied by the submerged volume (V) times the gravity (g) We can express this relation in the equation:
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.